Pulse Biosciences Insider Trades: Uecker Sells 45K, Ends with 284,406 Shares

Rhea-AI Filing Summary

Darrin Uecker, Pulse Biosciences (PLSE) Chief Technology Officer and director, reported multiple scheduled trades under a Rule 10b5-1 plan on September 16-17, 2025. He sold 25,000 shares on 9/16 and 20,000 shares on 9/17 at weighted average prices of $16.28 and $16.21 respectively, and purchased shares the same days at an exercise price of $4 under stock options and via market purchases. After the reported transactions his beneficial ownership of common stock is stated as 284,406 shares. Several $4 stock options with various exercisable dates are listed, and the Form notes the trades were executed pursuant to a 10b5-1 plan adopted June 12, 2025.

Positive

• Executed trades under a documented Rule 10b5-1 plan, reducing insider timing concerns
• Reported beneficial ownership increased to 284,406 shares after the transactions
• Form discloses weighted-average sale price ranges and offers full price breakdown on request

Negative

• Insider sold 45,000 shares (25,000 on 9/16 and 20,000 on 9/17), representing a reduction in holdings at the time of sale
• Some derivative positions show zero remaining after transactions, which may reduce future option-driven purchases

Insights

Financial Analyst

TL;DR: Insider used a 10b5-1 plan to sell 45,000 shares while materially increasing direct holdings to 284,406 shares.

The Form 4 shows coordinated purchases and sales on September 16-17, 2025 under a pre-established Rule 10b5-1 plan adopted June 12, 2025. Reported sales total 45,000 shares at weighted average prices of $16.28 and $16.21. Reported acquisitions (including option exercises/market purchases) increased reported beneficial ownership to 284,406 shares. Options with $4 exercise prices and multiple underlying-share counts are disclosed, with varying post-transaction derivative totals. For investors, the filing documents insider liquidity executed under a trading plan while net direct ownership increased.

Corporate Governance Expert

TL;DR: Transactions were executed under a documented 10b5-1 plan; disclosure appears complete and includes weighted-average sale prices.

The filing explicitly states the trades were effected pursuant to a Rule 10b5-1 trading plan adopted June 12, 2025, and provides weighted-average sale price ranges and an undertaking to provide per-price breakdowns if requested. Signature is by attorney-in-fact. The Form lists both direct holdings and derivative positions and references vesting tied to employment agreements. From a compliance perspective, the filing contains required details for scheduled insider trades.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

UECKER DARRIN

(Last) (First) (Middle)

C/O PULSE BIOSCIENCES, INC.

3957 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2025		M(1)		25,000	A	$4	147,872	D
Common Stock	09/16/2025		S(1)		25,000	D	$16.28(2)	122,872	D
Common Stock	09/17/2025		M(1)		20,000	A	$4	142,872	D
Common Stock	09/17/2025		S(1)		20,000	D	$16.21(3)	122,872	D
Common Stock	09/17/2025		M		61,534	A	$4	184,406	D
Common Stock	09/17/2025		M		100,000	A	$4	284,406	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4	09/16/2025		M(1)			25,000	09/08/2019(4)	09/20/2025	Common Stock	25,000	$0	81,534	D
Stock Option (right to buy)	$4	09/17/2025		M(1)			20,000	09/08/2019(4)	09/20/2025	Common Stock	20,000	$0	61,534	D
Stock Option (right to buy)	$4	09/17/2025		M			61,534	09/08/2019(4)	09/20/2025	Common Stock	61,534	$0	0	D
Stock Option (right to buy)	$4	09/17/2025		M			100,000	09/08/2019(5)	09/20/2025	Common Stock	100,000	$0	0	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025.

2. The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $15.49 to $16.78 per share. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes upon request by the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price within the range.

3. The price in column 4 is the weighted average price per share sold. The price per share actually received by the Reporting Person ranged from $16.00 to $16.44 per share.

4. Options granted in connection with Reporting Person's hire became fully vested upon the four year anniversary of his Start Date, September 8, 2019, pursuant to the terms of his Employment Agreement dated September 8, 2015.

5. Incentive stock options granted in connection with Reporting Person's hire became fully vested upon the four year anniversary of his Start Date, September 8, 2019, pursuant to the terms of his Employment Agreement dated September 8, 2015.

	/s/ Kenneth B. Stratton, as Attorney-in-Fact	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did PLSE insider Darrin Uecker report on Form 4?

The Form 4 reports purchases and sales on September 16-17, 2025 including sales of 25,000 and 20,000 shares and multiple acquisitions and option-related transactions.

How many PLSE shares does Darrin Uecker beneficially own after these transactions?

The filing states he beneficially owns 284,406 common shares following the reported transactions.

Were the trades part of a pre-established plan?

Yes. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted June 12, 2025.

At what prices were the sales executed?

Sales were reported at weighted average prices of $16.28 (range $15.49–$16.78) and $16.21 (range $16.00–$16.44) per share.

What stock option details are disclosed?

The Form lists multiple stock options with a $4 exercise price, exercisable dates tied to September 8, 2019, and expirations on September 20, 2025, with varying underlying-share counts reported.